Health Insurance

The recent approval of Aduhelm (aducanumab), which treats Alzheimer’s disease and carries an expected annual price tag of $56,000, has brought increased attention to high-cost drugs approved through the FDA’s accelerated approval pathway. While Medicare and its beneficiaries likely will be most impacted by the costs of the drug, as Alzheimer’s disease is most prevalent among
0 Comments
The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S.—and now we’re about to find out. After a nearly 20-year dry spell in new treatments for Alzheimer’s disease, the
0 Comments
Prescription drug spending has again returned to the policy agenda, with Congress and the Administration developing proposals to target drug prices. Though attention in current federal actions is largely focused on Medicare and private insurance drug prices, federal legislation also has been recently introduced or enacted that would affect Medicaid prescription drug policy. In 2019,
0 Comments
With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the public (66%) say that the
0 Comments
Key Findings The latest KFF Health Tracking Poll finds majorities of the public saying many current health care proposals being discussed by lawmakers are important priorities for Congress to focus on in the coming months, and few (less than one five) saying each of the health priorities “should not be done.” While majorities of the
0 Comments
As the coronavirus pandemic took shape in the U.S. in the early months of 2020, there was some uncertainty about how it would impact the financial performance of health insurers. Hospitals, physicians, and other health care providers cancelled elective procedures to free up beds, staff and supplies early in the pandemic and to limit unnecessary
0 Comments
A new analysis of health insurers’ financial data suggests that they remained profitable across markets in 2020 due in part to an unprecedented decrease in health spending and utilization in the spring as the COVID-19 pandemic led to massive shutdowns. The analysis examines insurers’ 2020 data for four distinct markets: Medicare Advantage, Medicaid managed care,
0 Comments